Development asset linked to GenSight Biologics in public FDA and regional records.
pharma · Retinitis Pigmentosa
GenSight Biologics
GenSight Biologics S.A.
GenSight Biologics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Company details
- Status
- Public
- HQ
- paris, FR
- Founded
- 2013
- Employees
- 34
- Programs
- 2
- Drugs
- 2
- Patents
- 0
GenSight Biologics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
GenSight Biologics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
lenadogene nolparvovec
Sensory organs (S01)Sensory organs (S01) compound in GenSight Biologics's portfolio.